Homepage > Company > Media > Pharma News > 2022 > Istesso’s Idiopathic Pulmonary Fibrosis Candidate Gains Fast Track

Istesso’s Idiopathic Pulmonary Fibrosis Candidate Gains Fast Track

The FDA has granted Fast Track status to UK-based Istesso’s BS2320 drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF), a chronic disease that causes lung scarring.

BS2320 is a metabolic reprogramming agent that has already shown promise in reducing symptoms and remodeling fibrotic tissue in rheumatoid arthritis patients.

The company plans to launch a clinical study in IPF patients beginning in 2023. BS2320 has also received Orphan Drug status for treatment of IPF.

The Fast Track designation is designed to expedite reviews of drugs to treat serious conditions and fill an unmet medical need.

About Istesso

Istesso is a drug discovery and development company working in the field of immunometabolism. Istesso pipeline of pre-clinical and clinical assets act by reprogramming metabolism to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. Istesso was founded in 2017 as the holding company for Modern Biosciences Ltd.

December 12, 2022

https://www.fdanews.com/

Read also

FDA approves AstraZeneca’s FASENRA for asthma in children

The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.

Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.